FIELD: medicine.
SUBSTANCE: proposed is a method for expanding a range of therapeutic doses of glial growth factor 2 (GGF2) when GGF2 is used for promoting myelination, including selecting a patient afflicted with a disease or disorder associated with reduced levels of myelination, administering GGF2 and a Mek1/Erk pathway inhibitor, whereby GGF2-mediated myelination occurs at higher doses of GGF2 than without administering a Mek1/Erk pathway inhibitor.
EFFECT: technical result is optimizing the therapeutic dose of GGF2, in particular, in its definition as 500 ng ± 15 % with the restriction of adverse effects - inhibition of myelination at high concentrations of GGF2 due to the Mek1/Erk inhibitor effect.
5 cl, 12 dwg
